COVID-19 vaccination in Chad

Last updated

COVID-19 vaccination in Chad
DateJune 4, 2021 (2021-06-04)
Cause COVID-19 pandemic

COVID-19 vaccination in Chad is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

Contents

Chad began its vaccination program on 4 June 2021, initially after receiving 200,000 doses of the Sinopharm BIBP vaccine donated by China. [1] As of 10 June 2021, 5,324 doses have been administered. [2]

History

Timeline

June 2021

Vaccinations started on 4 June, initially with 200,000 doses of the Sinopharm BIBP vaccine donated by China. By the end of the month 11,390 doses had been administered. [3]

July 2021

By the end of the month 26,511 doses had been administered. [3]

August 2021

By the end of the month 51,697 doses had been administered. [3]

September 2021

By the end of the month 130,369 doses had been administered. [3]

October 2021

By the end of the month 224,180 doses had been administered while 1% of the target population had been fully vaccinated. [3]

November 2021

By the end of the month 258,618 doses had been administered while 1% of the target population had been fully vaccinated. [3]

December 2021

By the end of the month 330,522 doses had been administered while 1% of the target population had been fully vaccinated. [3]

January 2022

By the end of the month 392,157 doses had been administered while 2% of the target population had been fully vaccinated. [3]

February 2022

By the end of the month 412,309 doses had been administered while 147,640 persons had been fully vaccinated. [3]

March 2022

By the end of the month 1,640,446 doses had been administered while 755,755 persons had been fully vaccinated. [3]

April 2022

By the end of the month 2,347,168 doses had been administered while 2,087,559 persons had been fully vaccinated. [3]

Progress

Cumulative vaccinations in Chad [4]

Related Research Articles

<span class="mw-page-title-main">Sinopharm BIBP COVID-19 vaccine</span> Vaccine against COVID-19

The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2 Vaccine, not to be confused with the similar product name of CoronaVac.

<span class="mw-page-title-main">COVID-19 vaccination in Zimbabwe</span> Plan to immunize against COVID-19

On 22 February 2021, Zimbabwe launched their national COVID-19 vaccination program using the Sinopharm BIBP vaccine. As of 17 June 2022, 6,260,228 people have received their first dose, 4,598,703 have received their second dose, and 851,874 have received a third dose.

On 29 January 2021, Algeria launched a COVID-19 vaccination campaign, a day after receiving its first shipment of 50,000 doses of the Russia's Sputnik V vaccine. As of 6 June 2021, around 2.5 million doses have been administered. Algeria is currently vaccinating its population with both Sputnik V and Oxford-AstraZeneca vaccines.

The COVID-19 vaccination in Morocco is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Angola is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. As of 15 June 2021, Angola has administered 1,314,375 doses of vaccines.822,109 people with the first dose and 492,266 people fully vaccinated. Angola began their vaccination program shortly after receiving their first shipment of Oxford AstraZeneca vaccine in early March 2021.

On 23 February 2021, Senegal began its national vaccination program against the COVID-19. As of 10 March, 68,205 people in Senegal have been able to be vaccinated.

<span class="mw-page-title-main">COVID-19 vaccination in Africa</span> Immunisation programme against COVID-19 in Africa

COVID-19 vaccination programs have begun in many countries and territories in Africa. In June 2021, the World Health Organization predicted that 47 of Africa's 54 nations would fall short of the aim of vaccinating 10% of their people by September 2021. In June, Africa accounted for fewer than 1% of worldwide vaccine doses delivered. Africa received in total less than 2% of the 3 billion vaccination doses provided globally.

<span class="mw-page-title-main">COVID-19 vaccination in Ghana</span> Plan to immunize against COVID-19

COVID-19 vaccination in Ghana began on Monday 1 March 2021 after the country became the first recipient of the Oxford-AstraZeneca COVID-19 vaccine as part of the COVAX initiative. As of 6 June 2021, Ghana has administered 1,230,000 vaccine doses.

<span class="mw-page-title-main">COVID-19 vaccination in Bhutan</span> Plan to immunize against COVID-19

Bhutan has promised a free COVID-19 vaccination to all of its citizens, both inside and outside the country. It started mass vaccinations on 27 March 2021.

<span class="mw-page-title-main">COVID-19 vaccination in Nigeria</span> Plan to immunize against COVID-19

COVID-19 vaccination in Nigeria is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Vaccination began on 5 March 2021. As of 28 February 2022, 17,914,944 people have received their first dose a COVID-19 vaccine, and 8,197,832 have received their second dose.

<span class="mw-page-title-main">COVID-19 vaccination in Sri Lanka</span> Plan to immunize against COVID-19

COVID-19 vaccination in Sri Lanka is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in response to the ongoing pandemic in the country. As of late July, the Sinopharm BIBP vaccine accounted for 78% of the total 13.8 million vaccines obtained by Sri Lanka to date. The United States donated over 1.5 million Moderna vaccine through COVAX.

COVID-19 vaccination in Burundi is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Burundi was one of the last nation states in the world to commence vaccination against COVID-19. This was mostly due to the government's refusal to vaccinate the population throughout most of 2021. In February 2021, Thaddee Ndikumana, the health minister of Burundi, said his country was more concerned with prevention measures. "Since more than 95% of patients are recovering, we estimate that the vaccines are not yet necessary," local media reported.

COVID-19 vaccination in Cameroon is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Djibouti is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Egypt is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Equatorial Guinea is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Eswatini is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in the Central African Republic is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in Comoros is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

COVID-19 vaccination in the Democratic Republic of the Congo is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

References

  1. Bazzara-Kibangula, Aurélie (6 June 2021). "Le Tchad lance sa campagne de vaccination contre le Covid-19" (in French). RFI. Retrieved 11 June 2021.
  2. "owid/covid-19-data". GitHub. Retrieved 19 June 2021.
  3. 1 2 3 4 5 6 7 8 9 10 11 Africa COVID-19 dashboard (World Health Organization).
  4. "owid/covid-19-data". GitHub. Retrieved 7 March 2021.